Abstract:Genetic medicine is offering hope as new therapies are emerging for many previously untreatable diseases. The eye is at the forefront of these advances, as exemplified by the approval of Luxturna® by the United States Food and Drug Administration (US FDA) in 2017 for the treatment of one form of Leber Congenital Amaurosis (LCA), an inherited blindness. Luxturna® was also the first in vivo human gene therapy to gain US FDA approval. Numerous gene therapy clinical trials are ongoing for other eye diseases, and novel delivery systems, discovery of new drug targets and emerging technologies are currently driving the field forward. Targeting RNA, in particular, is an attractive therapeutic strategy for genetic disease that may have safety advantages over alternative approaches by avoiding permanent changes in the genome. In this regard, antisense oligonucleotides (ASO) and RNA interference (RNAi) are the currently popular strategies for developing RNA-targeted therapeutics. Enthusiasm has been further fuelled by the emergence of clustered regularly interspersed short palindromic repeats (CRISPR)-CRISPR associated (Cas) systems that allow targeted manipulation of nucleic acids. RNA-targeting CRISPR-Cas systems now provide a novel way to develop RNA-targeted therapeutics and may provide superior efficiency and specificity to existing technologies. In addition, RNA base editing technologies using CRISPR-Cas and other modalities also enable precise alteration of single nucleotides. In this review, we showcase advances made by RNA-targeting systems for ocular disease, discuss applications of ASO and RNAi technologies, highlight emerging CRISPR-Cas systems and consider the implications of RNA-targeting therapeutics in the development of future drugs to treat eye disease.

Therapeutic Applications of CRISPR/Cas9 Gene Editing Technology for the Treatment of Ocular Diseases

Unleashing the potential of CRISPR multiplexing: Harnessing Cas12 and Cas13 for precise gene modulation in eye diseases

Applications Of Crispr/Cas9 In Retinal Degenerative Diseases

Genome editing in the treatment of ocular diseases

Exploring the Potential and Challenges of CRISPR Delivery and Therapeutics for Genetic Disease Treatment

Delivery strategies for CRISPR/Cas genome editing tool for retinal dystrophies: challenges and opportunities

Genetic engineering and the eye

Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing

Precision genome editing in the eye

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Novel Therapeutic Approaches for the Treatment of Retinal Degenerative Diseases: Focus on CRISPR/Cas-Based Gene Editing

Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy

Exploring retinal degenerative diseases through CRISPR-based screening

The Potential of Gene Editing Technologies in the Treatment of Hereditary Retinal Diseases

Development and application of CRISPR/Cas9 technologies in genomic editing.

CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases

RNA-targeting strategies as a platform for ocular gene therapy

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications

CRISPR Interference–Potential Application in Retinal Disease

The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy